Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving investigational agents at time of registration, or at any time while on study and during the 4 weeks preceding enrollment
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Investigational drugs: Patients who are currently receiving another investigational drug are not eligible
Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Use of any other investigational or study agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients may not be receiving any other investigational agents while on study
Patients must not currently be receiving any other investigational agents
Patients must not be receiving any other investigational anti-cancer agents while on study
Patients may not be receiving any other investigational agents while on study
Patients must not be receiving or planning to receive any other investigational agents
Patients may not be receiving any other investigational agents while on study treatment
Other anticancer agents and investigational agents should not be given while the subject is on study treatment
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed\r\n* CYP2C9 agents: patients who are currently receiving drugs that are moderate to strong inducers or inhibitor of CYP2C9 are not eligible\r\n* P-glycoprotein: patients who are currently receiving drugs that are potent inhibitors of p-glycoprotein are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
Patients who are currently receiving another investigational drug
Patients who are currently receiving other anticancer agents
Participants who are receiving or have received any other investigational agents within 14 days of enrollment
Subject is currently being treated with other investigational agents.
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
Patients receiving ongoing treatment with any other investigational agents are not eligible
Patients may not be receiving any other investigational agents
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents
Patients may not be receiving or have received any other investigational agents during/or within 1 month prior
Participants may not be receiving any other investigational agents; patients may not be receiving any other treatment for their rectal cancer during study participation and within 30 days prior to study treatment
Participants who are receiving any other investigational agents
Participants cannot receive treatment with any other investigational agents during protocol therapy
Participants who are receiving any other investigational agents
Patients receiving any other investigational agents are ineligible
Participants who are receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible
Patients receiving any other investigational agents are excluded
Subjects who are receiving any other investigational agents
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Receiving any other investigational agents or any other anti-cancer therapy
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients receiving any other investigational agents
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients receiving any other investigational agents
Patients may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents during the proposed treatment cycle.
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patient is receiving any other investigational agents.
Participants who are receiving any other investigational agents
Subjects who are currently receiving another investigational drug are not eligible
Subjects who are currently receiving any other anti-cancer agents are not eligible
Currently receiving any other investigational agents
Participants may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Patients receiving ongoing treatment with any other investigational agents are not eligible
Participants may not be receiving any other research study agents
Participants may not be receiving any other study agents for at least 7 days prior to enrollment
Receiving other investigational agents or not yet completed 30 days since completion of an investigational study
Subjects may not be receiving any investigational agents within 30 days prior to start of study treatment
Participants may not be receiving any other investigational study agents or treatment for their cancer
Receiving any other investigational agents
Participants may not be receiving any other investigational agents
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents.
Patients receiving any other investigational agents.
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Receiving any other investigational agents
Patients must not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Currently receiving any other investigational agents
Receiving any other investigational agents for their lymphoma
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
EXCLUSION - TREATMENT: Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents within 21 days of the first dose of study drug
Currently receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible.
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible.
Patients who are currently receiving another investigational drug are not eligible
Patients who are receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving anti-platelet agents are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are receiving any other investigational agents
Patients receiving any other anticancer or investigational drug therapy
EXCLUSION CRITERIA FOR REGISTRATION: Currently receiving any other investigational agents or systemic cancer therapy
Anti-cancer Agents\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Prior treatment with other anti-cancer agents
EXCLUSION - INFUSION: Currently receiving any investigational agents or radiotherapy within 4 weeks prior to entering the study
Participants who are receiving any other investigational agents
TREATMENT EXCLUSION: Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Participant receiving any other investigational agents within 30-days of enrollment nor during study participation
Patients may not be receiving any other investigational agents; (i.e. 28-day washout period from prior investigational drug is required)
Patients who are receiving any other investigational agents
Participants may not be receiving any other investigational agents
Receiving any other investigational agents
Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
Participants who are receiving any other investigational agents
Patients receiving any other investigational agents
Participants may not be receiving any other study agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Other investigational agents: ?4 weeks
Patients who are receiving any other anti-cancer or investigational drug therapy are ineligible
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational therapy
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents are excluded
Patients receiving any other investigational agents
Patients may not be receiving any other anti-neoplastic investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other therapeutic investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents, or have received investigational agents within 4 weeks of beginning treatment
Patients may not be receiving (or received prior to enrollment) any other investigational agents for metastatic disease.
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents for treatment of their kidney cancer
Patients who are receiving other investigational agents
Patients who are actively receiving any other investigational agents
Subjects may not receive any other concomitant investigational agents
Patients who are receiving any other investigational agents
Patient must not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants may not be receiving any other study agents
Patients receiving concurrent investigational chemotherapeutic agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents or other tumor-directed therapy.
Subjects who are receiving any other investigational agents. Prior immunotherapy, topotecan and temozolomide are allowed
Patients who are receiving any other investigational agents
Patients receiving other investigational agents.
Patients who are receiving any other investigational agents.
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents. A minimum washout period of 28 days is required prior to the initiation of on study treatment.
Patient is receiving other investigational agents
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents).
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Patients who are receiving any other investigational agents
STRATUM A: Participants receiving any other investigational agents
STRATUM B: Participants receiving any other investigational agents
STRATUM C: Participants receiving any other investigational agents
Patients may not be receiving any other investigational agents.
Currently receiving any other investigational agents
Patients who are currently receiving another investigational therapy are excluded
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Patients may not be receiving any other investigational agents for the treatment of their breast cancer
Currently receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are receiving any other investigational agents
Participants may not be receiving any other investigational agents targeting histiocytosis
Patients receiving any other investigational agents are ineligible
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair
Patients who are receiving any other anticancer or investigational agents
Patients must not be receiving any other investigational agents
Patients may not be receiving any other investigational agents within 30 days of registration
Patients must not be receiving any other investigational agents
Current or anticipated use of other investigational agents
Patients receiving other investigational agents
Patients who are receiving any other investigational agents
Patients receiving any other investigational drug therapy
Receiving any other investigational agents or any other anti-cancer therapy
Patients may not be receiving any other investigational agents.
Currently receiving any other investigational agents
Patients who are receiving any other investigational agents
Subjects who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents.
Patients who are receiving any other investigational agents.
Patients who are currently receiving or have previously received any other investigational agents within 3 weeks prior to entering the study
Participants who are currently receiving other anticancer agents.
Participants who are receiving any other investigational agents, or any other anti-cancer therapy during study treatment
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other anti-neoplastic agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents =< 28 days prior to study treatment
Participants who are receiving any other investigational agents
Patients receiving any other investigational agents within 30 days of receiving zydelig
Patients who are receiving any other investigational agents
Receiving any other investigational agents, or has received an investigational agent within the last 30 days
Subjects receiving any other investigational agents
Patients receiving any other investigational agents
Patients who are receiving any other investigational agents
Subjects who are receiving any other investigational agents
Patients receiving other investigational agents
Participants who are receiving any other investigational agents
Patients receiving any other investigational agents
Patients receiving any concurrent investigational agents
Patients who are receiving any investigational agents
Patients who are receiving any other investigational agents or other tumor-directed therapy
Patients receiving any other investigational agents
Patients may not be receiving any other investigational agents; a 2 week wash-out period for investigational agents is required before registration
Subjects may not be receiving any other investigational agents
Currently receiving any other investigational agents
Concomitant use of other investigational agents.
Patients who are receiving any other investigational agents within 28 days before start of study treatment
Subjects may not be receiving other investigational agents
Patients may not be receiving any other investigational agents =< 14 days from registration
Patients who are receiving any other investigational agents or have within the last 28 days
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Subjects receiving any other investigational agents
Receiving any other investigational agents within 14 days prior to enrollment
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other anticancer agents.
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents; any prior investigational agents must be stopped at least 14 days (2 week washout) prior to registration
Patients who are receiving any other investigational agents are ineligible
Patients who are receiving any other investigational agents
Patients should not have received any other investigational agents within the past 4 weeks
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Subjects receiving other investigational agents
Patients who are receiving any other investigational agents
Is currently receiving another investigational therapy
Currently receiving any other investigational agents
Patients may not be receiving any other investigational agents for the treatment of non-small cell lung cancer
Patients are permitted to receive investigational imaging agents while on study
Patients who are receiving any other investigational agents (with exception of imaging agents)
Patients who are receiving any other investigational agents; however, prior enrollment on a study using investigational agents is acceptable
Patients who are receiving any other investigational agents within the preceding 4 weeks
Patients may not be receiving any other investigational agents
Currently receiving any other investigational agents or received any within the past 28 days
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Subjects receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients receiving any other investigational agents
Patients receiving any investigational agents
Patients receiving any other investigational agents
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
Patients receiving any other investigational agents or immunotherapy
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents within the preceding 4 weeks
Patients receiving any other investigational chemotherapeutic agents within 28 days prior to the first dose of trial treatment
Subjects receiving any other investigational agents
Patients who are currently receiving any other investigational agents.
Patients who are receiving any investigational agents
Patients who are receiving any investigational agents
Subjects receiving any other investigational or standard antineoplastic agents
Patients receiving any other investigational agents or are unable to be treated with doxorubicin, cyclophosphamide, and paclitaxel
Subjects who are currently receiving any other investigational agents
Patients who are currently receiving another investigational drug are NOT eligible for either Stratum
Patients may not be receiving any other investigational agents
Currently receiving any other investigational agents
Subjects who are actively receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Patients who are receiving any other investigational agents
Subjects receiving any other investigational agents
Currently receiving investigational agents that are intended as treatments of recurrent GBM.
Receiving other anti-cancer or investigational therapy during study treatment, apart from those agents specified in the study protocol
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents.
Currently receiving any other investigational agents
Currently receiving any investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Currently receiving any other investigational agents
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents within 4 weeks of the start of the study treatment.
Currently receiving any investigational agents
Patients receiving any other investigational agents and or more that two different chemotherapy regimens for treatment of metastatic disease
Subjects may not be receiving any other investigational agents or anticancer therapies.
Currently receiving radiotherapy, biological therapy, or any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents; if patients are currently part of or have participated in any clinical investigation with an investigational drug, the last administration of the investigational study should be at least 1 month prior to dosing
Patients may not be receiving any other investigational and/or anti-cancer agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy
Subjects who are receiving any other investigational agents
Must not be currently receiving any investigational drugs
Currently receiving any other investigational agents
Current therapy with any other investigational agents.
Patients who are receiving any other investigational agents
Patient may be receiving bone targeted agents
Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Subjects who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Current or anticipated use of other investigational agents
Investigational agents/therapies
Patients who are receiving any other investigational agents
TREATMENT: Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks
Currently receiving any other investigational agents that are intended as treatments of the relapsed tumor
Currently receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible.
Patients who are currently receiving other anti-cancer agents are not eligible.
Past history of other investigational agents
Patients may not be receiving any other investigational agents with the intent to treat the disease (imaging agents are acceptable)
Patients who are receiving concurrent chemotherapy, or who are currently receiving other investigational chemotherapeutic agents or concurrently receiving radiation
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational therapeutic agents
Subjects may not be receiving any other investigational agents
Patients who are receiving other investigational therapeutic agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Ongoing use of investigational agents or use of investigational agents within the last four weeks
Are being treated with other investigational agents.
Patients may not be receiving any other investigational agents; use of over-the-counter herbal medications will also be excluded
Patients who are receiving any other investigational agents
Subjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibited
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Participants may not be receiving any other study agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Subjects receiving any other investigational or standard antineoplastic agents
Patients who are receiving any other investigational agents
Currently receiving any investigational agents or received any tumor vaccines within the previous 6 weeks
Patients may not be receiving any other investigational agents
Subjects is receiving any other investigational agents for the treatment of prostate cancer
Patients may not be receiving any other investigational agents
Subjects must not be receiving any other investigational agents
Patients receiving any other investigational agents.
Patients may not be receiving any other investigational agents
Must not be receiving any other investigational agents within 14 days of first dose of azacitidine (day 7)
Patients receiving any other investigational agents
Patients may not be receiving any other investigational agents and/or other therapy for their cancer
Participants may not be receiving any other study agents, and may not have received any other investigational agents within 6 months prior to study entry
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
Patient must not be receiving any other investigational agents
Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment
Patients who are receiving any other investigational agents
Patients who are receiving any other anticancer or investigational drug therapy are not eligible
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients receiving any other study agents
Patients who are receiving any other investigational agents
EXCLUSION CRITERIA FOR REGISTRATION: patients who are receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Simultaneous primary invasive cancers or patients currently receiving any other investigational agents at time of study enrollment. Patients may have received investigational agents in the past. No washout time period is required.
Patient may not be receiving any other investigational drug
Anticancer Agents: participants who are currently receiving other anticancer agents
Current receipt of any other investigational agents
Patients receiving any other investigational agents or anti-cancer agents within 30 days other than mibefradil dihydrochloride, hypofractionated RT, or corticosteroids as described in this clinical protocol during treatment
Participants may not be receiving any other investigational agents
Patients must not be currently receiving other anti-cancer agents
Patients who are receiving any other investigational agents
Participants who are currently receiving any other investigational agents.
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Participants may not have received any other investigational agents in the previous 3 months
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
Concomitant use of other investigational agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents, or exposure to any investigational drug or placebo within 4 weeks of study treatment
Patients who are receiving any other investigational agents
Receiving any other investigational agents within 4 weeks of beginning study treatment
Currently receiving any other investigational agents
Patients may not be receiving any other investigational agents
Subjects receiving any other investigational or standard antineoplastic agents
Patients who have received any other investigational agents within the preceding 4 weeks
Currently receiving any other investigational agents.
Patients who are currently receiving another investigational drug
Patients who are currently receiving other anti-cancer agents
Patients who are receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Receiving any other investigational agents =< 28 days prior to registration
Patients receiving any other investigational agents are ineligible
Participants who are receiving any other investigational agents
Participants who are receiving any investigational agents are not eligible
Participants receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Subjects who are receiving any other investigational agents
Patients receiving any other investigational agents are ineligible
The subject is receiving any other investigational agents
Patients receiving any other investigational agents
Patients who are currently receiving another investigational drug
Patients may not currently be receiving any other investigational agents for leukemia
Patients may not be receiving any other investigational agents
TUMOR BIOPSY SEQUENCING: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
TREATMENT: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Current or anticipated use of other investigational agents
Patients who are receiving any other investigational agents
Patients must not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Subjects receiving any other investigational agents
Participants may not be receiving any other investigational agents for treatment of their cancer
Patients who are currently receiving another investigational drug
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents
Patients who are receiving any other biologic, cytotoxic or investigational agents
Any other investigational agents within the past 4 weeks
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents with the intention to treat their cancer (imaging trials are acceptable)
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
Subjects may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Ongoing use of any other investigational or study agents
Participants who are receiving any other investigational agents
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
Patients receiving any other investigational agents
Receiving other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other study or off protocol anti-cancer agents
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents are ineligible
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Current or anticipated use of other investigational agents
Patients who are receiving any other investigational agents
Patients who have received any other investigational agents within the last 4 weeks
Patients may not be receiving any additional investigational agents or radiation therapy
Patients who are currently receiving another investigational drug are not eligible
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to registration
PHASE II: Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to randomization
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients may not be receiving any other investigational agents within 4 weeks of starting the study treatment and during the study period
Patients who are currently receiving another investigational drug are not eligible
Patients who are receiving any other investigational agents
Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents for melanoma
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
Patients may not be receiving any other investigational agents
Not currently receiving other investigational drugs
Current use of any investigational agents
Patients who are receiving any other investigational agents are not eligible
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Treatment with other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
PHASE II: Patients may not be receiving any other investigational agents while on study
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients must not be receiving any other investigational agents
Patients currently receiving other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Currently receiving any investigational agents or have received any tumor vaccines within the previous six weeks
May not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Participants receiving any other investigational agents
Patients who are receiving any other investigational agents for cancer
Patients who are receiving any other investigational agents
Active treatment with any other investigational agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Patients may not be planning to receive any other investigational agents
Patients must not be planning to receive other anti-cancer agents including investigational agents while on protocol treatment
Subject who is receiving any other investigational agents;
Patients who are receiving any other investigational agents
Not receiving any other investigational agents
Patients may not be receiving any other investigational agents
Receiving any investigational agents currently or within 30 days prior to study screening
Patients must not be receiving any other investigational agents
Patients may not have received any other investigational agents within 4 weeks of study entry
Subjects receiving any other investigational agents
Currently receiving any other investigational agents
Receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients receiving any other investigational agents
Currently receiving any other investigational agents
Patients may not be receiving any other investigational agents
Currently receiving any other investigational agents
Patients who are receiving any other investigational agents
Subjects who are receiving or have received any other investigational agents within 28 days prior to day 1 of treatment in this study
Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
Concomitant use of other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Current or anticipated use of other investigational agents
Receiving any other investigational agents at the time of registration
Patients who are receiving any other investigational agents
Patients must not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Use of any other investigational agents
Currently receiving any investigational agents or have received any tumor vaccines within previous 4 weeks
Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
Patients may not be receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anticancer agents are not eligible
Patients who are receiving any other investigational agents
Current use of other investigational agents
Use of investigational agents within 30 days
Currently receiving any other active investigational agents
Participants who are receiving any other investigational agents after ASCT
Subjects receiving any other investigational agents
Patients may not be receiving any other investigational agents\r\n* Note: a wash-out period of 2 weeks prior to registration is required for any patient to be enrolled in the study
Participants may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Patients may not be receiving any other investigational agents within 2 weeks prior to registration
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patient receiving any other investigational agents
Patients may not be receiving any other investigational cancer-directed agents
Actively receiving any investigational agents
Patients receiving any other investigational agents within 30 days prior to the first dose of trial treatment
Participants who are receiving any other investigational agents within 14 days before the first dose of study drug
Participants may not be receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other anti-cancer or investigational drug therapy are excluded
Use of any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Patients receiving other investigational agents
Patients receiving any other investigational agents or any additional anti-cancer agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Subjects receiving other investigational agents are not eligible
May not be receiving any other study agents
Patients may not be receiving any other investigational agents; patients cannot be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy for the purposes of anti-cancer treatment
Participants may not be receiving any other study agents
Patients who are receiving any other investigational agents
Currently receiving investigational agents
Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
Patients may not be on any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
PHASE II: Participants may not be receiving any other investigational agents
Participants may not be receiving any biologics or investigational agents within 3 weeks
Patients who are receiving any other investigational agents or who have received pomalidomide in the past
Patients receiving other anti-neoplastic agents are excluded
Subjects may not be receiving any other investigational agents
Participants receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients should not be receiving any other investigational agents
Ongoing therapy with other investigational agents. Patients may not be receiving any other investigational agents.
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy
Participants receiving any other study agents
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
Participants may not be receiving any other investigational anticancer agents
Participants may not be currently receiving any other experimental agents
Currently receiving any other investigational agents that are intended as treatments of GBM
Participants may not be receiving any other study agents
Patients receiving any other investigational agents for cancer treatment
Patients may not be receiving any other investigational agents while on study treatment
Participants may not be receiving any other study agents
Participants may not be receiving any other study agents.
Patients who are currently receiving any other investigational agents.
Participants may not be receiving any other study agents
Patients may not be receiving any other investigational agents
Participants may not be receiving any other study agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents while on study
Patient receiving any other investigational agents
Patient must not be receiving any other investigational agents
Patients who are receiving any investigational agents
Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than androgen deprivation
Patients currently receiving other investigational drugs are not eligible
Patient must not be receiving any other investigational agents
Currently receiving any investigational agents or registration on another therapy based trial
Patients who are receiving any investigational agents.
Current or anticipated use of other investigational agents
Patients may not be receiving any other investigational agents
Participants may not be receiving any other study agents
Patients receiving any other chemotherapy or investigational agents
Patients who are receiving any other investigational agents
Participants may not be receiving any other study agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents; any prior investigational products must be stopped at least 14 days (2-week washout) prior to registration
Currently receiving any other investigational agents
Participants may not be receiving any other investigational agents
Subjects may not receive any other concomitant investigational agents
Subjects receiving any other investigational agents
Participants who are currently receiving any other investigational agents
Participants may not be receiving any other study agents
Subjects may not be receiving any other standard or investigational anticancer agents, with the exception of hormonal therapy
Any investigational agents
Subjects receiving other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents.
Participants may not be receiving any other investigational agents
Receiving any other investigational agents including those for symptom management
Receiving any other investigational agents currently, or within time limits specified above prior to study day 1
Participants may not be receiving any other study agents
Patients receiving any other investigational agents
Patients receiving other investigational agents
Patients may not be receiving any other investigational agents nor have received any investigational drug 30 days prior to enrollment
Participants who are receiving concurrent therapy with other investigational agents
Patient receiving any investigational or experimental agents other than checkpoint blockade immunotherapy
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
Receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients should not be receiving any other investigational agents
Patients must not be receiving other investigational agents or concurrent anticancer therapy
Patients should not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Patients who are receiving any other investigational agents or commercial agents with the intent to treat the malignancy
Patients may not be receiving any other investigational agents
Receiving any other investigational agents
Other investigational agents: ?4 weeks
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents for anticancer treatment within 3 weeks of starting study medication
Patient may not be receiving any other antineoplastic agents
Currently receiving other anti-cancer agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants may not be receiving any other investigational agents
Patients receiving any other investigational agents
Participants who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are currently receiving other anti-cancer agents are excluded from this trial
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are currently receiving any other investigational agents
Receiving any other investigational agents
Patients may not be receiving any other investigational agents.
Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)
Patients receiving any other investigational agents
Patients must have discontinued immunotherapy or other systemic therapy including investigational agents at least 4 weeks prior to entering the study and have recovered from adverse events due to those agents. Patients must agree to not receive any other investigational agents during study participation.
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents or other medications for the treatment of their malignancy
Participants who are receiving any other investigational agents
Patients may not receive any other anti-neoplastic or investigational agents within 3 weeks of study enrollment; patients may not be receiving any other investigational agents during treatment on protocol
Patients receiving any other investigational agents
Patients receiving any other investigational anti-cancer agents
Patients receiving any other investigational agents are ineligible
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Current receiving any other anti-neoplastic investigational agents
Current therapy with other investigational agents.
Patients receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are currently receiving other anti-cancer agents are not eligible
Patients may not be receiving any other investigational agents
Receiving any other investigational agents or any other anti-cancer therapy
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents or have received immunotherapy
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
Currently receiving any other investigational agents
Patients may not be receiving any additional investigational agents or radiation therapy
Currently receiving any other investigational agents
Participants receiving any other anti-cancer or investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents within 28 days before start of study treatment
Receiving any other investigational agents simultaneously or within 3 weeks following ablation procedure
Participants may not be receiving any other study agents
Currently receiving any other investigational agents that are intended as treatments of recurrent GBM
Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
Patients may not be receiving any other investigational agents; a minimum 4 week “washout” period is required
Participants may not be receiving any other study agents at the time of first treatment
Patients should not be receiving any other investigational agents
Investigational agents/therapies
Investigational agents within 4 weeks of randomization.
Participants may not be receiving other investigational agents.
Patients may not be receiving any investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients who are receiving any other investigational agents
Patient must not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients currently receiving other investigational agents
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents.
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Patients receiving any other investigational agents are ineligible
Patients may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Participants may not be receiving any other study agents
Patients receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients receiving any other investigational agents
Patients who are receiving any other investigational agents
Patients planning on receiving other investigational agents while on this study
Patients receiving other investigational therapies
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents or have received other investigational agents for at least 3 weeks
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies except hormonal maintenance treatment for prostate cancer
Patients who are receiving any other investigational agents
Patients may not be receiving any other investigational agents within 7 days of registration
Patients who are receiving any other investigational agents
Patients who are currently receiving another investigational drug are not eligible
Currently receiving any other investigational agents
Patients who are receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational agents
Currently receiving any other investigational medication or therapy
Participants who are receiving any other investigational agents
Participants who are receiving any other investigational agents
Subjects who are receiving any other investigational agents
All cancer patients receiving chemotherapy agents
Participants may not be receiving any other study agents
Patient receiving antiplatelet agents
Patients currently receiving any other investigational agents;
Participants who are receiving any other investigational agents
Participants may not be receiving any other investigational agents within 30 days of enrollment or during this study
Participants who are receiving any other investigational agents
Patients may not be receiving any other investigational agents.\r\n* Note: it is acceptable to be on combination therapy including either sorafenib, regorafenib, and/or sunitinib.
Patients who are receiving any other investigational agents
Subjects who are receiving any other investigational agents or have received another investigational drug in the last 30 days
Patients who are receiving any other investigational agents
Subjects may not be receiving any investigational agents
Research participants receiving any other investigational agents
No restrictions on use of other investigational agents
Patients who are receiving any other investigational agents
Participants who are receiving any other investigational agents; participants who are receiving standard of care induction therapy on a clinical trial may be eligible after discussion with the overall principal investigator
Patients receiving any other investigational agents are ineligible
Participants who are receiving any other investigational agents
Patients receiving any other study agents
Patient may be receiving bone targeted agents
Participants receiving any other investigational agents
Participants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable
Current or anticipated use of other investigational agents
Patient must not be receiving any other investigational agents
Participants may not be receiving any other investigational agents for treatment of GVHD or underlying disease for at least 7 days
Patient must not be actively receiving any other investigational agents
Patients who are receiving other investigational agents will be permitted on study, at the discretion of the principal investigator
Participants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionary
Current use of any other investigational agents
Participants may not be receiving investigational agents
Receiving any other investigational agents =< 6 months prior to registration
Receiving any other investigational agents =< 6 months prior to Registration
Active use of any other investigational agents
Current use of any other investigational agents
Participants may not be receiving any other investigational agents
Receiving any other investigational agents
Current use of any other investigational agents
Patients may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Currently receiving investigational agents in a clinical trial
Participants may not be receiving any other investigational agents
Currently receiving investigational agents in a clinical trial
Patients may not be receiving any other investigational agents
Receiving any other investigational agents
Receiving any other investigational, anticoagulation, and/or chemotherapy agents
Participants who are receiving any other investigational agents
Current use of any other investigational agents
Participants receiving any other investigational agents
Participant is receiving any other investigational agents
Participants may not be receiving any other investigational agents
Participants who are currently receiving any other investigational agents or have received investigational agents within the past 3 months will be excluded
Participants may not be receiving any other investigational agents within past 3 months
Participants may not have received any other investigational agents in the previous 3 months
Participants may not be receiving any other investigational agents
Patients who are receiving any other investigational agents
Receipt of any other investigational agents =< 3 months prior to randomization, except innocuous agents with no known interaction with the study agents (e.g., standard dose multivitamins or topical agents for limited skin conditions), at the discretion of the protocol lead investigator at each participating site
Patients receiving any other investigational agents are ineligible
Ongoing therapy with other investigational agents
Patients may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents during the study
Participants may not be receiving any other investigational agents
Participants may not be receiving any other investigational agents
Receiving any other investigational agents
Patient may not be receiving any other investigational agents
Patients who are receiving any other investigational agents (in the past 28 days) or herbal medication (within 1 day)
Patients must not receive any other investigational agents while on study
Patients may not be receiving any other investigational agents
Patients may not be receiving any other investigational agents
Patients should not be taking other investigational agents
Participants who are receiving any other investigational agents
Patients may not be receiving any other investigational agents
Current use of any investigational agents
Patient must not be receiving an investigational drug
Patients may not be currently receiving any other investigational agents within 4 weeks of study registration
Patients receiving any other study agents
Patients must not currently be using other investigational agents
Participants receiving other investigational agents
Participants who are receiving any other investigational agents
Women who are receiving any other investigational agents
Patients should not be taking other investigational agents
Receiving any investigational agents
Subjects may not be receiving any investigational agents
Current receipt of any other investigational agents or any additional anti-cancer agents for this or any other disease
Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 1 day)
Patients who are receiving any other investigational agents
Ongoing treatment with any other investigational agents
Patients receiving any other investigational agents within 4 weeks of starting the study
Receipt of any other investigational agents or any additional anti-cancer agents
Patients may not be receiving any other investigational agents
Donors receiving experimental therapy or investigational agents.
Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 7 days)
Patients who are receiving any other investigational agents
Patients receiving
Patients who are receiving any other investigational agents
Patients who are currently receiving another investigational therapy are excluded
